The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

GSK plc (LSE/NYSE: GSK) today announced that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY ...

The FDA has approved a prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

Current prevention measures, including flu vaccines and antiviral medications, have shown limitations due to low uptake or lack of effective vaccines in the case of herpes. With this in mind ...

The company has also filed for FDA approval of its flu+Covid combination vaccine, mRNA-1083. If approved, it will be the first in the US to offer protection against flu and Covid-19 in a single shot.

An infectious disease physician says the pace of the flu vaccine rollout for vulnerable groups is "disappointing" amid concerns the 2025 season will be the worst yet.

Australians are being urged to roll up their sleeves for a flu vaccine amid rising cases of influenza. It’s an opportune time to think about other vaccines too, particularly because some ...

As the flu season approaches in Australia, new flu vaccines for 2025 have become available. Many individuals have likely received notifications from their healthcare providers regarding the stock of ...

It’s that time of year when flu vaccines are becoming available in Australia. You may have received an email from your GP clinic or a text message from your pharmacy telling you they’re in stock.

DAHD has permitted the commercial use of the H9N2 vaccine, developed by ICAR-NIHSAD, Bhopal (Representational Image) In response to the recent outbreaks of Avian Influenza across India, the Department ...

For healthy adults and children outside these groups, a flu vaccine costs around A$20–30. The vaccines are widely available at GPs and pharmacies, and through workplace programs. Flu vaccines ...

Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral ...